ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,567.19
1.06%
US Tech 100
19,846.40
1.04%
Dow Jones
39,375.87
0.17%
Brent Oil
86.535
-0.91%
Bitcoin
56,351.98
-1.12%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BeiGene Ltd (BGNE)

  7. BeiGene Ltd (BGNE) News

BGNE

BeiGene (BGNE)

BeiGene Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BGNE
DateTimeSourceHeadlineSymbolCompany
04/17/20232:32PMBusiness WireBeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023NASDAQ:BGNEBeiGene Ltd
04/17/20232:30PMBusiness WireMapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023NASDAQ:BGNEBeiGene Ltd
04/17/20232:30PMGlobeNewswire Inc.MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023NASDAQ:BGNEBeiGene Ltd
04/13/20237:00AMBusiness WireBeiGene Expands Presence in Latin America With Opening of Brazil OfficeNASDAQ:BGNEBeiGene Ltd
03/30/20237:00AMBusiness WireBeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health EquityNASDAQ:BGNEBeiGene Ltd
03/29/20234:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
03/21/20237:00AMBusiness WireBeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New JerseyNASDAQ:BGNEBeiGene Ltd
03/20/20235:38PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
03/10/20236:49PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
02/27/20237:38AMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:BGNEBeiGene Ltd
02/27/20237:08AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
02/27/20237:00AMBusiness WireBeiGene Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:BGNEBeiGene Ltd
02/24/20237:00AMBusiness WireBeiGene to Present at Cowen’s 43rd Annual Healthcare ConferenceNASDAQ:BGNEBeiGene Ltd
02/24/20237:00AMBusiness WireBeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in ChinaNASDAQ:BGNEBeiGene Ltd
02/14/20234:26PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BGNEBeiGene Ltd
02/13/20233:57PMEdgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:BGNEBeiGene Ltd
02/10/20234:54PMEdgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:BGNEBeiGene Ltd
02/06/20236:37AMPR Newswire (Canada)Le Québec devient la première province à rembourser PrBRUKINSA® (zanubrutinib) pour le traitement de la macroglobulinémie de WaldenströmNASDAQ:BGNEBeiGene Ltd
02/06/20236:37AMPR Newswire (Canada)Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemiaNASDAQ:BGNEBeiGene Ltd
02/03/20237:00AMBusiness WireNew Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer CareNASDAQ:BGNEBeiGene Ltd
02/01/20237:00AMBusiness WireBeiGene to Present at Upcoming Investor ConferencesNASDAQ:BGNEBeiGene Ltd
01/31/20234:27PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
01/23/20232:59PMValueWalkFive Best And Worst Performing Large-Cap Stocks In Dec 2022NASDAQ:BGNEBeiGene Ltd
01/19/20235:03PMBusiness WireBRUKINSA® Approved in the U.S. for Chronic Lymphocytic LeukemiaNASDAQ:BGNEBeiGene Ltd
01/19/20237:00AMBusiness WireBRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRANASDAQ:BGNEBeiGene Ltd
01/18/20238:27AMBusiness WireBeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug ListNASDAQ:BGNEBeiGene Ltd
01/17/20235:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
01/17/20235:00PMBusiness WireBeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers SymposiumNASDAQ:BGNEBeiGene Ltd
01/12/20234:53PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
01/06/202310:47AMValueWalkThese Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022NASDAQ:BGNEBeiGene Ltd
 Showing the most relevant articles for your search:NASDAQ:BGNE

Your Recent History

USOTC
BLLB
Bell Buckle (PK)
USOTC
ERHE
ERHC Energy (CE)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
NASDAQ
NVDA
NVIDIA
COIN
SHIBUSD
SHIBA INU
USOTC
SPZI
Spooz (PK)
AMEX
SPY
SPDR S&P 500
NASDAQ
TSLA
Tesla
NASDAQ
AVXL
Anavex Life Sciences
USOTC
CYDY
CytoDyn (QB)
COIN
BTCUSD
Bitcoin
USOTC
GTVH
Golden Triangle Ventures (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
BLEG
Branded Legacy (PK)
USOTC
PSRU
Valiant Eagle (PK)
USOTC
ENZC
Enzolytics (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved